The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics.

Autor: Gezehagn Kussia G; Genomics and Bioinformatics Bio and Emerging Technology Institute, Addis Ababa 5954, Ethiopia.; Institute of Biotechnology Addis Ababa University, Addis Ababa 1176, Ethiopia., Tessema TS; Institute of Biotechnology Addis Ababa University, Addis Ababa 1176, Ethiopia.
Jazyk: angličtina
Zdroj: Journal of immunology research [J Immunol Res] 2024 Aug 09; Vol. 2024, pp. 1804038. Date of Electronic Publication: 2024 Aug 09 (Print Publication: 2024).
DOI: 10.1155/2024/1804038
Abstrakt: The advancement of genetic engineering has revolutionized the field of immunology by allowing the utilization of intrinsic antibody structures. One of the biologics that are being produced by recombinant antibody technology is single-chain fragments variable (scFv). Genes of variable regions, the heavy and light chains that are genetically linked into a single transcript by a short flexible linker peptide, are used to generate this fragment from cellular and synthetic libraries. The specificity and affinity of these molecules are comparable to those of parental antibodies. Fusion with marker proteins and other potent molecules improves their stability, circulation half-life, activity, and efficient purification. Besides, this review comprises construction protocols, therapeutics, and diagnostic applications of scFv, as well as related challenges. Nonetheless, there are still issues with efficacy, stability, safety, intracellular administration, and production costs that need to be addressed.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2024 Getachew Gezehagn Kussia and Tesfaye Sisay Tessema.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje